Analysis of the EAP, page-198

I have read your posts with great interest.

Any thoughts on XPO1 inhibitors, specifically KPTI, whom are conducting a 230-patient trial right now for COVID-19. I know the side effects can be horrible, which led to a failed Adcom last year (only to have the FDA overrule the panel and approved anyway a few months later). KPTI claim the COVID-19 trial is low dosage and taken by pill every two days.

Silviu always said that Vaccines and Antivirals shall have an important future role in helping people with this life-threatening viral infection. Whatever treatments are offered, some people shall fail them as you said, and we can come in as a salvage therapy once the patient has ARDS or about to enter ARDS.

I completely agree that MESO is flying under the radar of the American press, but is one of the leaders in the race for an effective and approved FDA therapeutic.